Possible symptoms of infection may include: redness or other color changes swelling pain warmth drainage You should report any of these symptoms to a healthcare professional immediately
Liu L, Dong Y, Ye M, Jin S, Yang J, Joosse ME, et al
Federal Programs May Expand Access, But Timeline Is Unclear The Trump administration announced the BALANCE model in December 2025, which aims to expand access to GLP-1s in Medicare and Medicaid by negotiating lower prices with manufacturers
Effective treatment depends on: Proper wavelength selection Accurate energy calibration Skin type assessment Appropriate treatment intervals Personalized planning ensures optimal targeting of follicles during the anagen phase
but lower doses led to more modest weight loss:Lower doses had a more favourable side effect profile, too:This triple agonism aims to relieve some of the side effects of GLP1s (nausea, muscle loss), and increase weight loss (so the dose can be lowered)Sources: New obesity drugs - nature.com/articles/d4158 Triple agonist Retatrutide phase 2 trial - nejm.org/doi/full/10.10 full article: openread.academy/en/paper/readi Breakdown of the article: The article discusses the development of new obesity drugs that aim to provide greater and healthier weight loss